Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series a Financing; Unveils Strategic Focus
Published in Hepatitis Weekly, July 28th, 2008
Dicerna Pharmaceuticals, Inc. (www.dicerna.com), an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology(TM), announced a second closing of its Series A financing, receiving a total of $8.4 million in additional venture capital from new investor Abingworth and existing investors Oxford Bioscience Partners and Skyline Ventures. With this additional capital, Dicerna has completed a $21.4 million Series A financing round. Pursuant to this second closing, Vincent J. Miles, Ph.D., venture partner at Abingworth has joined Dicerna's board of directors. Prior to Abingworth, Dr. Miles was senior vice president of business development at Alnylam...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2008-07-28)
More Articles from Hepatitis Weekly
- Universidad de Granada
Stem cells from umbilical cord used in the treatment of hepatic diseases - University of California - San Diego
Improved culture system for hepatitis C virus infection - Acute Hepatitis
Reports by Z. Zhang and co-researchers describe recent advances in acute hepatitis - Acute Hepatitis
Research from University of Delhi in acute hepatitis provides new insights - Alcoholism
Research from E. Ishibashi and colleagues provide new insights into alcoholism - Breast Cancer
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
